Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses

Official Title

Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study)

Brief Summary

The main objectives are: - To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. - To identify variables associated to higher risk of bleeding.

Status

Completed

Conditions

COVID-19

Eligibility Criteria

Inclusion Criteria:

- Patients infected with COVID-19 treated with higher than recommended
thromboprophylaxis doses.

- Admission to hospital.

Exclusion Criteria:

- Patients treated with ECMO (Extracorporeal membrane oxygenation).

Eligibility Gender

All

Eligibility Age

Minimum: N/A ~ Maximum: N/A

Countries

Spain

Locations

Manuel Monreal
Badalona, Barcelona, Spain

Investigators

Manuel Monreal, Study Chair
Germans Trias i Pujol Hospital

NCT Number

NCT04380779

MeSH Terms

COVID-19

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Manuel Monreal

Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA